Swedish Orphan Biovitrum AB (publ) BIOVF · OTC
$46.00 +7.48% (+$3.20)
Summary
60 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Revenue grew by 14% a year over the last 3 years.
- Out of every 100 SEK of revenue, 24 SEK is left as free cash.
- It earns 14 SEK a year on every 100 SEK of invested capital.
What to watch
- Earnings per share fell by 45% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 116.8 SEK for 1 SEK of yearly profit. Over the last five years it was 80.6 SEK on average.
Valuation in detailIs it growing?
SlowlyRevenue (SEK)
Diluted EPS (SEK)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 20%. Earnings per share fell by 45% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 SEK of revenue goes
- Cost of sales 48 SEK
- Research and development 12 SEK
- Sales and administration 2.6 SEK
- Taxes and other 25 SEK
- Net profit 4.6 SEK
Net profit, industry median (Medical - Pharmaceuticals) 4.8 SEK
Out of every 100 SEK of revenue, 4.6 SEK is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.